Treatment and prophylaxis of bleeding in patients with haemophilia

Rationale: 1

Long term prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency and treatment of breakthrough bleeding episodes during regular prophylaxis

Rationale 1,6

Congenital protein C deficiency

Rationale 1,6

Treatment of severe postpartum haemorrhage

(NovoSeven®)

Rationale 1,6

Treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU)) – in patients with congenital haemophilia with low titre inhibitors (BU <5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX

(Cevenfacta®) (activated)

Rationale 1,6

For treating moderately severe or severe haemophilia B

Brand : Hemgenix

Rationale 1,6

NICE Guidance 

Haemorrhage in patients with haemophilia A or B with antibodies to factors VIII or IX, acquired haemophilia, factor VII deficiency, or Glanzmann's thrombasthenia

Rationale 1

Haemophilia A and Von Willebrand disease- prevention and treatment of bleeding

Rationale 1

Treatment and prophylaxis of bleeding in patients aged ≥2 years with severe or moderate haemophilia A (≤5% endogenous plasma factor VIII activity)

NICE TA1051

Routine prophylaxis of bleeding episodes in patients aged ≥12 years, weighing ≥35kg, with severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors, or severe haemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors

NICE TA1073